Company news
MacroGenics, Inc. news in 2019
MacroGenics, Inc.'s news releases, calls and decks from 2019, newest first.
MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
December 18, 2019
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
December 10, 2019
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
November 5, 2019
MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019
November 5, 2019
MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call
October 29, 2019
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
October 24, 2019
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
October 21, 2019